BIBLIOGRAFIA

• World Health Organization warns of growing "crisis of suffering". http://www.who.ch/whr/1997/presse.htm.
  
• Omata, M. 1998. Treatment of Chronic Hepatitis B Infection. N. Engl. J. Med. 339(2):114-5.
  
• Kioko Ono-Nita, S.; Kato, N.; Shiratori, Y.; Omata, M. 2001. Current Options for the Therapy of Chronic Hepatitis B Infection. Current Infectious Disease Reports. 3:137-42.
  
• Lai, C. L.; Chien, R. N.; Leung, N. W.; Chang, T. T., Guan, R.; Tai, D. I.; Ng, K.Y.; Wu, P.C.; Dent, J. C.; Barber, J., et al. 1998. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 339(2):61-8.
  
• Chien, R. N.; Liaw, Y. F.; Atkins, M. 1999. Pretherapy alanine transaminase level as a determinant for hepatitis B and antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology. 30(3):770-.
  
• Ono-Nita, S. K.; Kato, N.; Shiratori, Y.; Lan, K. H.; Yoshida, H.; Carrilho, F. J.; Omata, M. 1999. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J. Clin. Invest. 103(12):1635-40.
  
• Ono-Nita, S. K.; Kato, N.; Shiratori, Y.; Masaki, T.; Lan, K. H.; Carrilho, F. J.; Omata, M. 1999. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology. 29(3):939-45.
  
• Da Silva, L. C.; Pinho, J. R. R.; Stinik, R.; Fonseca, L. E. P.; Carrilho, F. J. 2001. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B. J. Gastroenterol. 36:476-85.
  
• Singh, N.; Gayowski, T.; Wannstedt, C. F.; Wagener, M. M.; Marino, I. R. 1997. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation. 63(10):1415-9.
  
• Klein, M.; Geoghegan, J.; Schmidt, K.; Bockler, D.; Korn, K.; Wittekind, C.; Scheele, J. 1997. Conversion of recurrent delta-positive hepatitis B infection to seronegativity with famciclovir after liver transplantation. Transplantation. 64(1):162-3.
  
• de Man, R. A.; Marcellin, P.; Habal, F.; Desmond, P.; Wright, T.; Rose, T.; Jurewicz, R.; Young, C. 2000. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology. 32(2):413-7.
  
• Ono, S. K.; Kato, N.; Shiratori, Y.; Kato, J.; Goto, T.; Schinazi, R. F.; Carrilho, F. J.; Omata, M. 2001. The polimerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest. 107(4):449-55.
  
• Perrillo, R.; Schiff, E.; Yoshida, E.; Statler, A.; Hirsch, K.; Wright, T.; Gutfreund, K.; Lamy, P.; Murray, A. 2000. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology. 32(1):129-34.
  
• Genovesi, E. V.; Lamb, L.; Medina, I.; Taylor, D.; Seifer, M.; Innaimo, S.; Colonno, R. J.; Standring, D. N.; Clark, J. M. 1998. Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother. 42(12):3209-17.
• Colonno, R. J. Identification of BMS-200475 as a novel and potent inhibitor of hepatitis B replication. www.thebody.com/anti497/bms.html
• Chowdhur Y. J. R. & Chowdhury, N.R. Bilirrubin metabolism and its disorders. In Kaplowitz, N. Liver and Biliary Disease. 2º ed. Baltimore, Williams & Wilkins. p. 154-170, 1996.
• Laudanna, A. A. Doenças Inflamatórias Intestinais. In: Laudanna, A. A., ed. Gastroenterologia Clínica. 1.ed. São Paulo, Livraria Editora Santos, 1990; p. 493-507.
• Pereira, A.; Suzuki, R. K. ; Bock, J. A. V.; Mincis, M. Diagnóstico Diferencial das Icterícias. In: Mincis, M. 1 ed. São Paulo, Lemos-Editorial, 1997; p. 578-585.
• Pereira Lima, J.; Pereira Lima, J. C. Colestase. In: Mincis, M. 1 ed. São Paulo, Lemos-Editorial, 1997; p. 578-585.
• Sherlock, S. and Dooley, J. Jaundice. In Sherlock, S. & Dooley, J. Diseases of Liver and Biliary System. 10th ed. Oxford, Blackwell Science, p. 201-16, 1997.
• Roy-Chowdhur Y. J. ; Jansen, P.L.M. Bilirrubin metabolism and its disorders. Hepatology: a text of liver disease. In: Zakin, D. & Boyer. 3º ed. W. S. Sanders Company, p. 323-348.